And so I ask myself this question: Which gorilla of a global pharmaceutical company is going to corner the market on pharmaceutical cannabinoid molecules to be the supplier of those molecules to other pharmaceutical companies??? Pfizer's PC1 division already does this but is missing a big growth opportunity in that portfolio when it comes to active cannabinoid molecules. Looking forward to Mr. Pidduck disclosing the details of the pre-nup agreement with their "traditonal globla pharmaceutical partner". Traditional means they've been around for awhile and global means they are a big gorilla. The PC1 division of Pfizer is a B2B company within Pfizer, business to business, that sells directly to other pharmaceutical companies, a custom white label services.
We have to think outside the box a little bit as well when it comes to cannabinoid pharmaceutical molecules and in that they could exist as a stand alone formulation of only cannabinoid molecules as well as working in conjunction with existing traditional pharmaceutical molecules to enhance their effectiveness. I bring up this quiet point recalling the work at McMaster where cannabinoid molecules combined with traditional antibiotics increased their effectiveness against drug resistant bugs.
That adds a massive component of synergy from the perspective of a division like PC1, utilizing one group of new molecules to enhance the effectiveness of existing drugs. Rejuvenation of the life product cycle for an existing product, academically speaking, or simply something old becomes new and better again.